C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
C4 Therapeutics, Inc. (Nasdaq: CCCC) filed a Current Report on Form 8-K dated October 16, 2025. The filing reports the entry into a material definitive agreement for an underwritten public offering of equity securities. The offering is expected to close on October 17, 2025, subject to customary conditions.
Key Financial Metrics and Offering Details
The filing details a capital raise structured with common stock, pre-funded warrants, and two classes of warrants. Key financial figures include:
- Securities Issued: 21,895,000 shares of Common Stock and 28,713,500 Pre-Funded Warrants.
- Warrants Issued: 50,608,500 Class A Warrants and 50,608,500 Class B Warrants.
- Offering Price: $2.47 per Share (plus warrants) and $2.4699 per Pre-Funded Warrant (plus warrants).
- Estimated Net Proceeds (Initial): Approximately $117.0 million after underwriting discounts and expenses.
- Maximum Potential Proceeds: Approximately $341.7 million if all warrants are cash exercised in full.
- Use of Proceeds: Extends the Company's cash runway to the end of 2028.
Note: This filing does not provide historical revenue, profit, cash flow, or debt metrics. It focuses exclusively on the terms of the new capital raise.
Material Changes and Transaction Structure
The primary material change is the significant dilution of existing shareholders and the increase in cash liquidity resulting from the offering. The transaction structure includes:
- Pre-Funded Warrants: Exercisable immediately at $0.0001 per share; do not expire.
- Class A Warrants: Exercise price of $2.22. Expire on the earlier of 30 days after specific Phase 1b study data release or the fifth anniversary of issuance.
- Class B Warrants: Exercise price of $2.22. Expire on the fifth anniversary. Subject to mandatory exercise if the stock price exceeds $6.66 for 10 consecutive trading days after six months.
- Beneficial Ownership Limitation: Holders cannot exercise warrants if it would cause them to beneficially own more than 4.99% or 9.99% of outstanding shares (adjustable to 19.99% with notice).
Guidance, Risks, and Contingencies
Management commentary indicates the proceeds are intended to fund operations through the end of 2028. The filing includes standard forward-looking statement disclaimers regarding market conditions and closing risks.
Key Risks and Contingencies:
- Closing Conditions: The transaction is subject to customary closing conditions.
- Warrant Expiration Triggers: Class A warrants have a unique expiration tied to clinical data release (nine-month median follow-up data from the Phase 1b study of cemsidomide with elranatamab).
- Dilution: The issuance of warrants and pre-funded warrants represents a significant potential increase in share count.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $117.0 million.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification and covenant details.
- Monitor the status of the Phase 1b study of cemsidomide with elranatamab, as this data release triggers the expiration of Class A Warrants.
- Assess the impact of the 4.99%/9.99% beneficial ownership limitation on institutional investor participation.
- Confirm the updated cash runway and burn rate in subsequent quarterly filings (10-Q) to validate the "end of 2028" projection.